Cargando…
Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response
Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft-tissue sarcomas refractory to standard therapies. Inactivation of NF1 and subsequent upregulation of RAS/RAF/MEK/ERK signaling exist in the majority of MPNSTs. However, the lack of preclinical assessment of MEK inhibitors in MPNSTs hind...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303010/ https://www.ncbi.nlm.nih.gov/pubmed/35875109 http://dx.doi.org/10.3389/fonc.2022.903177 |
_version_ | 1784751758297268224 |
---|---|
author | Gu, Yihui Wang, Wei Li, Yuehua Li, Haibo Guo, Zizhen Wei, Chengjiang Long, Manmei Chung, Manhon Aimaier, Rehanguli Li, Qingfeng Wang, Zhichao |
author_facet | Gu, Yihui Wang, Wei Li, Yuehua Li, Haibo Guo, Zizhen Wei, Chengjiang Long, Manmei Chung, Manhon Aimaier, Rehanguli Li, Qingfeng Wang, Zhichao |
author_sort | Gu, Yihui |
collection | PubMed |
description | Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft-tissue sarcomas refractory to standard therapies. Inactivation of NF1 and subsequent upregulation of RAS/RAF/MEK/ERK signaling exist in the majority of MPNSTs. However, the lack of preclinical assessment of MEK inhibitors in MPNSTs hinders the clinical application as well as the development of combination therapy. To guide further clinical studies, we evaluated different MEK inhibitors in terms of efficacy, safety, and mechanism of adaptive response in treating MPNSTs. Using a MPNST tissue microarray, we found that p-ERK could serve as a biomarker for predicting the prognosis of MPNST patients as well as an effective therapeutic target. Through in vitro and in vivo experiments, we identified trametinib as the most potent MEK inhibitor for the treatment of MPNSTs. Mechanistically, reduced reactivation of the MAPK pathway and compensatory activation of the parallel pathways contributed to better efficacy. Our results provide a basis for the further clinical application of MEK inhibitors as single agents or combinational therapies. |
format | Online Article Text |
id | pubmed-9303010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93030102022-07-22 Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response Gu, Yihui Wang, Wei Li, Yuehua Li, Haibo Guo, Zizhen Wei, Chengjiang Long, Manmei Chung, Manhon Aimaier, Rehanguli Li, Qingfeng Wang, Zhichao Front Oncol Oncology Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft-tissue sarcomas refractory to standard therapies. Inactivation of NF1 and subsequent upregulation of RAS/RAF/MEK/ERK signaling exist in the majority of MPNSTs. However, the lack of preclinical assessment of MEK inhibitors in MPNSTs hinders the clinical application as well as the development of combination therapy. To guide further clinical studies, we evaluated different MEK inhibitors in terms of efficacy, safety, and mechanism of adaptive response in treating MPNSTs. Using a MPNST tissue microarray, we found that p-ERK could serve as a biomarker for predicting the prognosis of MPNST patients as well as an effective therapeutic target. Through in vitro and in vivo experiments, we identified trametinib as the most potent MEK inhibitor for the treatment of MPNSTs. Mechanistically, reduced reactivation of the MAPK pathway and compensatory activation of the parallel pathways contributed to better efficacy. Our results provide a basis for the further clinical application of MEK inhibitors as single agents or combinational therapies. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9303010/ /pubmed/35875109 http://dx.doi.org/10.3389/fonc.2022.903177 Text en Copyright © 2022 Gu, Wang, Li, Li, Guo, Wei, Long, Chung, Aimaier, Li and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gu, Yihui Wang, Wei Li, Yuehua Li, Haibo Guo, Zizhen Wei, Chengjiang Long, Manmei Chung, Manhon Aimaier, Rehanguli Li, Qingfeng Wang, Zhichao Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title_full | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title_fullStr | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title_full_unstemmed | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title_short | Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response |
title_sort | preclinical assessment of mek inhibitors for malignant peripheral nerve sheath tumors reveals differences in efficacy and adaptive response |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303010/ https://www.ncbi.nlm.nih.gov/pubmed/35875109 http://dx.doi.org/10.3389/fonc.2022.903177 |
work_keys_str_mv | AT guyihui preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT wangwei preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT liyuehua preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT lihaibo preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT guozizhen preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT weichengjiang preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT longmanmei preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT chungmanhon preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT aimaierrehanguli preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT liqingfeng preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse AT wangzhichao preclinicalassessmentofmekinhibitorsformalignantperipheralnervesheathtumorsrevealsdifferencesinefficacyandadaptiveresponse |